LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-20
Case ID: NM_015338.5_c.3184C_T_20261120_162954
Framework: ACMG/AMP 2015
Variant classification summary

NM_015338.5:c.3184C>T

ASXL1  · NP_056153.2:p.(Pro1062Ser)  · NM_015338.5
GRCh37: chr20:31023699 C>T  ·  GRCh38: chr20:32435896 C>T
Gene: ASXL1 Transcript: NM_015338.5
Final call
VUS
PM2 moderate BP4 supporting
All criteria require review: For research and educational purposes only.
Gene
ASXL1
Transcript
NM_015338.5
Protein
NP_056153.2:p.(Pro1062Ser)
gnomAD AF
1.610734928786931e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
VUS: PM2 (moderate) is met because gnomAD v4.1 shows an allele frequency of 1.61073e-05 with zero homozygotes.
2
VUS: BP4 (supporting) is met because the missense REVEL score is 0.018, below the 0.29 threshold.
Final determination: Under generic ACMG/AMP 2015 rules, one moderate pathogenic criterion and one supporting benign criterion do not independently satisfy any pathogenic, likely pathogenic, benign, or likely benign combination, so the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PS1 Not met Not met: p.Pro1062Ser has no documented previously established pathogenic same-amino-acid change in the available evidence.
clinvar
PS2 Not assessed Not assessed: no affected-proband, confirmed maternity and paternity, or family-history evidence is documented for this variant.
PS3 Not assessed Not assessed: no validated in vitro or in vivo assay of p.Pro1062Ser with documented controls or biological functional readout is available.
PS4 Not assessed Not assessed: no affected/control counts or variant-specific disease case observation were available to evaluate increased prevalence or calculate an odds ratio.
gnomad_v4
PM1 Not met Not met: Cancer Hotspots found no statistically significant hotspot for ASXL1 P1062, and no qualifying critical-domain evidence is available.
hotspots cosmic
PM2 Met Met at Moderate: gnomAD v4.1 AF is 1.61073e-05, below the 0.0001 generic PM2 cutoff, with 0 homozygotes.
gnomad_v2 gnomad_v4
PM3 N/A Not applicable: PM3 requires a recessive disorder, whereas the available ASXL1 germline disease context is dominant and no recessive inheritance is documented.
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 Not met Not met: the PM5 search contains zero same-residue candidates, and no different pathogenic missense change at Pro1062 is documented.
pm5_candidates clinvar
PM6 Not assessed Not assessed: no assumed-de novo observation in an affected patient or parental-testing information is documented.
PP1 Not assessed Not assessed: no affected-relative genotypes, phenotype data, pedigree, or informative meioses are documented for co-segregation.
PP2 Not assessed Not assessed: the available evidence does not establish both low benign missense variation and a common disease-causing missense mechanism for ASXL1.
oncokb
PP3 Not met Not met: missense REVEL score 0.018 is below the PP3 supporting threshold of >= 0.644.
revel
PP4 Not assessed Not assessed: no patient phenotype, family history, or specific disease diagnosis was supplied to judge highly specific phenotype evidence.
PP5 Not met Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Pathogenic or Likely pathogenic classification.
clinvar
BA1 Not met Not met: grpmax FAF is 1.533e-05 in gnomAD v4.1, far below the 0.05 BA1 threshold.
gnomad_v2 gnomad_v4
BS1 Not met Not met: the highest applicable grpmax FAF is 1.533e-05, far below the 0.01 generic BS1 threshold.
gnomad_v2 gnomad_v4
BS2 Not met Not met: gnomAD reports 0 homozygotes, with no documented healthy adult individual carrying the disease-relevant genotype.
gnomad_v2 gnomad_v4
BS3 Not assessed Not assessed: no validated in vitro or in vivo assay demonstrates preserved p.Pro1062Ser function or normal splicing with documented controls.
BS4 Not assessed Not assessed: no affected-family-member genotypes or phenotype-confirmed non-segregation observations are documented.
BP1 Not assessed Not assessed: loss-of-function biology is supported, but a citable source showing that ASXL1 disease variants are primarily truncating is absent.
BP2 Not assessed Not assessed: no pathogenic partner variant or parental/offspring phase result establishes the required cis or trans configuration for BP2.
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Met Met at supporting: missense REVEL score 0.018 meets the BP4 threshold of <= 0.29.
revel
BP5 Not met Not met: COSMIC records two somatic cancer occurrences but provides no disease case with an independently established alternate molecular basis.
cosmic
BP6 Not met Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Benign or Likely benign classification.
clinvar
BP7 N/A Not applicable: BP7 requires a synonymous variant, and this is a missense variant.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.